Anti-obesity medications in the management of heart failure with preserved ejection fraction: available evidence and next STEPS.
Heart Fail Rev
; 29(5): 939-944, 2024 Sep.
Article
en En
| MEDLINE
| ID: mdl-38965119
ABSTRACT
Obesity is associated with an increased risk of incident heart failure with preserved ejection fraction (HFpEF) and, among patients with existing heart failure, is associated with worse quality of life, higher symptom burden, and more HF hospitalizations. Anti-obesity medication (AOM) semaglutide has been shown to be efficacious at both causing intentional weight loss and improving HF symptom burden, with some evidence to suggest that HF clinical events may also be reduced. Additional ongoing trials of AOM in patients with cardiovascular disease, including HFpEF, will further improve insight into the potential role of managing obesity to improve HF status among patients with HFpEF and obesity.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Volumen Sistólico
/
Fármacos Antiobesidad
/
Insuficiencia Cardíaca
/
Obesidad
Límite:
Humans
Idioma:
En
Revista:
Heart Fail Rev
Asunto de la revista:
CARDIOLOGIA
Año:
2024
Tipo del documento:
Article
País de afiliación:
Estados Unidos